Last update Jan. 16, 2021
Sulfonylurea that stimulates endogenous insulin secretion. May cause hypoglycemia.
Indicated in the treatment of type 2 diabetes.
Oral administration, one daily dose
We did not find published data regarding the excretion of this substance through breast milk at the time this last update was completed.
Its pharmacokinetic characteristics (very high plasma protein binding and large volume of distribution) make it very unlikely its excretion into breast milk in significant amounts.
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
Diet, exercise, and breastfeeding improve blood sugar levels.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM